Global Cell and Gene Therapy Market Size, Share, Trends: By Therapy Type: Cell Therapy Types, Gene Therapy Types; By Type: Cell Type, Gene Type; By Delivery Mode: In Vivo, Ex Vivo; By Vector Type: Viral Vector, Non-viral Techniques; By Therapeutic Area: Oncology, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Cell and Gene Therapy Market Outlook:

The cell and gene therapy market size was valued at USD 17.4 billion in 2023, driven by the increasing prevalence of chronic disorders like cancer across the globe. The market size is anticipated to grow at a CAGR of 23.17% during the forecast period of 2024-2032 to achieve a value of USD 113.53 billion by 2032.

Cell and Gene Therapy Report Snapshots

Cell and Gene Therapy Size

Cell and Gene Therapy Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1   Preface
   1.1   Objectives of the Study
   1.2   Key Assumptions
   1.3   Report Coverage – Key Segmentation and Scope
   1.4   Research Methodology
2   Executive Summary
3   Global Cell and Gene Therapy Market Overview
   3.1   Global Cell and Gene Therapy Market Historical Value (2017-2023)
   3.2   Global Cell and Gene Therapy Market Forecast Value (2024-2032)
4   Vendor Positioning Analysis
   4.1   Key Vendors
   4.2   Prospective Leaders
   4.3   Niche Leaders
   4.4   Disruptors
5   Global Cell and Gene Therapy Market Landscape*
   5.1   Global Cell and Gene Therapy: Developers Landscape
       5.1.1   Analysis by Year of Establishment
       5.1.2   Analysis by Company Size
       5.1.3   Analysis by Region
   5.2   Global Cell and Gene Therapy: Product Landscape
       5.2.1   Analysis by Therapy Type
       5.2.2   Analysis by Indication
6   Global Cell and Gene Therapy Market Dynamics
   6.1   Market Drivers and Constraints
   6.2   SWOT Analysis
       6.2.1   Strengths
       6.2.2   Weaknesses
       6.2.3   Opportunities
       6.2.4   Threats
   6.3   PESTEL Analysis
       6.3.1   Political
       6.3.2   Economic
       6.3.3   Social
       6.3.4   Technological
       6.3.5   Legal
       6.3.6   Environment
   6.4   Porter’s Five Forces Model
       6.4.1   Bargaining Power of Suppliers
       6.4.2   Bargaining Power of Buyers
       6.4.3   Threat of New Entrants
       6.4.4   Threat of Substitutes
       6.4.5   Degree of Rivalry
   6.5   Key Demand Indicators
   6.6   Key Price Indicators
   6.7   Industry Events, Initiatives, and Trends
   6.8   Value Chain Analysis
7   Global Cell and Gene Therapy Market Segmentation (2017-2032)
   7.1   Global Cell and Gene Therapy Market (2017-2032) by Therapy Type
       7.1.1   Market Overview
       7.1.2   Cell Therapy Types
           7.1.2.1   Autologous Cell Therapy
           7.1.2.2   Allogenic Cell Therapy
       7.1.3   Gene Therapy Types
           7.1.3.1   Somatic Gene Therapy
           7.1.3.2   Germline Gene Therapy
   7.2   Global Cell and Gene Therapy Market (2017-2032) by Type
       7.2.1   Market Overview
       7.2.2   Cell Type
           7.2.2.1   Stem Cell
           7.2.2.2   Non-Stem Cell
       7.2.3   Gene Type
           7.2.3.1   Antigen
           7.2.3.2   Cytokine
           7.2.3.3   Tumor Suppressor
           7.2.3.4   Growth Factors
           7.2.3.5   Receptors
           7.2.3.6   Others
   7.3   Global Cell and Gene Therapy Market (2017-2032) by Delivery Mode
       7.3.1   Market Overview
       7.3.2   In Vivo
       7.3.3   Ex Vivo
   7.4   Global Cell and Gene Therapy Market (2017-2032) by Vector Type
       7.4.1   Market Overview
       7.4.2   Viral Vector
       7.4.3   Non-viral Techniques
   7.5   Global Cell and Gene Therapy Market (2017-2032) by Therapeutic Area
       7.5.1   Market Overview
       7.5.2   Oncology
       7.5.3   Cardiovascular Diseases
       7.5.4   Neurological Disorders
       7.5.5   Genetic Disorders
       7.5.6   Infectious Diseases
       7.5.7   Hematological Disorders
       7.5.8   Musculoskeletal Disorders
       7.5.9   Others
   7.6   Global Cell and Gene Therapy Market (2017-2032) by End User
       7.6.1   Market Overview
       7.6.2   Hospitals
       7.6.3   Cancer Care Centers
       7.6.4   Academic and Research Institutes
       7.6.5   Others
   7.7   Global Cell and Gene Therapy Market (2017-2032) by Region
       7.7.1   Market Overview
       7.7.2   North America
       7.7.3   Europe
       7.7.4   Asia Pacific
       7.7.5   Latin America
       7.7.6   Middle East and Africa
8   North America Global Cell and Gene Therapy Market (2017-2032)
   8.1   North America Cell and Gene Therapy Market (2017-2032) by Therapy Type
       8.1.1   Market Overview
       8.1.2   Cell Therapy Types
           8.1.2.1   Autologous Cell Therapy
           8.1.2.2   Allogenic Cell Therapy
       8.1.3   Gene Therapy Types
           8.1.3.1   Somatic Gene Therapy
           8.1.3.2   Germline Gene Therapy
   8.2   North America Cell and Gene Therapy Market (2017-2032) by Type
       8.2.1   Market Overview
       8.2.2   Cell Type
           8.2.2.1   Stem Cell
           8.2.2.2   Non-Stem Cell
       8.2.3   Gene Type
           8.2.3.1   Antigen
           8.2.3.2   Cytokine
           8.2.3.3   Tumor Suppressor
           8.2.3.4   Growth Factors
           8.2.3.5   Receptors
           8.2.3.6   Others
   8.3   North America Cell and Gene Therapy Market (2017-2032) by Delivery Mode
       8.3.1   Market Overview
       8.3.2   In Vivo
       8.3.3   Ex Vivo
   8.4   North America Cell and Gene Therapy Market (2017-2032) by Vector Type
       8.4.1   Market Overview
       8.4.2   Viral Vector
       8.4.3   Non-viral Techniques
   8.5   North America Cell and Gene Therapy Market (2017-2032) by Indication
       8.5.1   Market Overview
       8.5.2   Oncology
       8.5.3   Cardiovascular Diseases
       8.5.4   Neurological Disorders
       8.5.5   Genetic Disorders
       8.5.6   Infectious Diseases
       8.5.7   Hematological Disorders
       8.5.8   Musculoskeletal Disorders
       8.5.9   Others
   8.6   North America Cell and Gene Therapy Market (2017-2032) by End User
       8.6.1   Market Overview
       8.6.2   Hospitals
       8.6.3   Cancer Care Centers
       8.6.4   Academic and Research Institutes
       8.6.5   Others
   8.7   North America Global Cell and Gene Therapy Market (2017-2032) by Country
       8.7.1   United States of America
       8.7.2   Canada
9   Europe Global Cell and Gene Therapy Market (2017-2032)
   9.1   Europe Cell and Gene Therapy Market (2017-2032) by Therapy Type
       9.1.1   Market Overview
       9.1.2   Cell Therapy Types
           9.1.2.1   Autologous Cell Therapy
           9.1.2.2   Allogenic Cell Therapy
       9.1.3   Gene Therapy Types
           9.1.3.1   Somatic Gene Therapy
           9.1.3.2   Germline Gene Therapy
   9.2   Europe Cell and Gene Therapy Market (2017-2032) by Type
       9.2.1   Market Overview
       9.2.2   Cell Type
           9.2.2.1   Stem Cell
           9.2.2.2   Non-Stem Cell
       9.2.3   Gene Type
           9.2.3.1   Antigen
           9.2.3.2   Cytokine
           9.2.3.3   Tumor Suppressor
           9.2.3.4   Growth Factors
           9.2.3.5   Receptors
           9.2.3.6   Others
   9.3   Europe Cell and Gene Therapy Market (2017-2032) by Delivery Mode
       9.3.1   Market Overview
       9.3.2   In Vivo
       9.3.3   Ex Vivo
   9.4   Europe Cell and Gene Therapy Market (2017-2032) by Vector Type
       9.4.1   Market Overview
       9.4.2   Viral Vector
       9.4.3   Non-viral Techniques
   9.5   Europe Cell and Gene Therapy Market (2017-2032) by Indication
       9.5.1   Market Overview
       9.5.2   Oncology
       9.5.3   Cardiovascular Diseases
       9.5.4   Neurological Disorders
       9.5.5   Genetic Disorders
       9.5.6   Infectious Diseases
       9.5.7   Hematological Disorders
       9.5.8   Musculoskeletal Disorders
       9.5.9   Others
   9.6   Europe Cell and Gene Therapy Market (2017-2032) by End User
       9.6.1   Hospitals
       9.6.2   Cancer Care Centers
       9.6.3   Academic and Research Institutes
       9.6.4   Others
   9.7   Europe Global Cell and Gene Therapy Market (2017-2032) by Country
       9.7.1   United Kingdom
       9.7.2   Germany
       9.7.3   France
       9.7.4   Italy
       9.7.5   Others
10   Asia Pacific Global Cell and Gene Therapy Market (2017-2032)
   10.1   Asia Pacific Cell and Gene Therapy Market (2017-2032) by Therapy Type
       10.1.1   Market Overview
       10.1.2   Cell Therapy Types
           10.1.2.1   Autologous Cell Therapy
           10.1.2.2   Allogenic Cell Therapy
       10.1.3   Gene Therapy Types
           10.1.3.1   Somatic Gene Therapy
           10.1.3.2   Germline Gene Therapy
   10.2   Asia Pacific Cell and Gene Therapy Market (2017-2032) by Type
       10.2.1   Market Overview
       10.2.2   Cell Type
           10.2.2.1   Stem Cell
           10.2.2.2   Non-Stem Cell
       10.2.3   Gene Type
           10.2.3.1   Antigen
           10.2.3.2   Cytokine
           10.2.3.3   Tumor Suppressor
           10.2.3.4   Growth Factors
           10.2.3.5   Receptors
           10.2.3.6   Others
   10.3   Asia Pacific Cell and Gene Therapy Market (2017-2032) by Delivery Mode
       10.3.1   Market Overview
       10.3.2   In Vivo
       10.3.3   Ex Vivo
   10.4   Asia Pacific Cell and Gene Therapy Market (2017-2032) by Vector Type
       10.4.1   Market Overview
       10.4.2   Viral Vector
       10.4.3   Non-viral Techniques
   10.5   Asia Pacific Cell and Gene Therapy Market (2017-2032) by Indication
       10.5.1   Market Overview
       10.5.2   Oncology
       10.5.3   Cardiovascular Diseases
       10.5.4   Neurological Disorders
       10.5.5   Genetic Disorders
       10.5.6   Infectious Diseases
       10.5.7   Hematological Disorders
       10.5.8   Musculoskeletal Disorders
       10.5.9   Others
   10.6   Asia Pacific Cell and Gene Therapy Market (2017-2032) by End User
       10.6.1   Hospitals
       10.6.2   Cancer Care Centers
       10.6.3   Academic and Research Institutes
       10.6.4   Others
   10.7   Asia Pacific Global Cell and Gene Therapy Market (2017-2032) by Country
       10.7.1   China
       10.7.2   Japan
       10.7.3   India
       10.7.4   ASEAN
       10.7.5   Australia
       10.7.6   Others
11   Latin America Global Cell and Gene Therapy Market (2017-2032)
   11.1   Latin America Cell and Gene Therapy Market (2017-2032) by Therapy Type
       11.1.1   Market Overview
       11.1.2   Cell Therapy Types
           11.1.2.1   Autologous Cell Therapy
           11.1.2.2   Allogenic Cell Therapy
       11.1.3   Gene Therapy Types
           11.1.3.1   Somatic Gene Therapy
           11.1.3.2   Germline Gene Therapy
   11.2   Latin America Cell and Gene Therapy Market (2017-2032) by Type
       11.2.1   Market Overview
       11.2.2   Cell Type
           11.2.2.1   Stem Cell
           11.2.2.2   Non-Stem Cell
       11.2.3   Gene Type
           11.2.3.1   Antigen
           11.2.3.2   Cytokine
           11.2.3.3   Tumor Suppressor
           11.2.3.4   Growth Factors
           11.2.3.5   Receptors
           11.2.3.6   Others
   11.3   Latin America Cell and Gene Therapy Market (2017-2032) by Delivery Mode
       11.3.1   Market Overview
       11.3.2   In Vivo
       11.3.3   Ex Vivo
   11.4   Latin America Cell and Gene Therapy Market (2017-2032) by Vector Type
       11.4.1   Market Overview
       11.4.2   Viral Vector
       11.4.3   Non-viral Techniques
   11.5   Latin America Cell and Gene Therapy Market (2017-2032) by Indication
       11.5.1   Market Overview
       11.5.2   Oncology
       11.5.3   Cardiovascular Diseases
       11.5.4   Neurological Disorders
       11.5.5   Genetic Disorders
       11.5.6   Infectious Diseases
       11.5.7   Hematological Disorders
       11.5.8   Musculoskeletal Disorders
       11.5.9   Others
   11.6   Latin America Cell and Gene Therapy Market (2017-2032) by End User
       11.6.1   Hospitals
       11.6.2   Cancer Care Centers
       11.6.3   Academic and Research Institutes
       11.6.4   Others
   11.7   Latin America Global Cell and Gene Therapy Market (2017-2032) by Country
       11.7.1   Brazil
       11.7.2   Argentina
       11.7.3   Mexico
       11.7.4   Others
12   Middle East and Africa Global Cell and Gene Therapy Market (2017-2032)
   12.1   Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Therapy Type
       12.1.1   Market Overview
       12.1.2   Cell Therapy Types
           12.1.2.1   Autologous Cell Therapy
           12.1.2.2   Allogenic Cell Therapy
       12.1.3   Gene Therapy Types
           12.1.3.1   Somatic Gene Therapy
           12.1.3.2   Germline Gene Therapy
   12.2   Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Type
       12.2.1   Market Overview
       12.2.2   Cell Type
           12.2.2.1   Stem Cell
           12.2.2.2   Non-Stem Cell
       12.2.3   Gene Type
           12.2.3.1   Antigen
           12.2.3.2   Cytokine
           12.2.3.3   Tumor Suppressor
           12.2.3.4   Growth Factors
           12.2.3.5   Receptors
           12.2.3.6   Others
   12.3   Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Delivery Mode
       12.3.1   Market Overview
       12.3.2   In Vivo
       12.3.3   Ex Vivo
   12.4   Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Vector Type
       12.4.1   Market Overview
       12.4.2   Viral Vector
       12.4.3   Non-viral Techniques
   12.5   Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Indication
       12.5.1   Market Overview
       12.5.2   Oncology
       12.5.3   Cardiovascular Diseases
       12.5.4   Neurological Disorders
       12.5.5   Genetic Disorders
       12.5.6   Infectious Diseases
       12.5.7   Hematological Disorders
       12.5.8   Musculoskeletal Disorders
       12.5.9   Others
   12.6   Middle East and Africa Cell and Gene Therapy Market (2017-2032) by End User
       12.6.1   Hospitals
       12.6.2   Cancer Care Centers
       12.6.3   Academic and Research Institutes
       12.6.4   Others
   12.7   Middle East and Africa Global Cell and Gene Therapy Market (2017-2032) by Country
       12.7.1   Saudi Arabia
       12.7.2   United Arab Emirates
       12.7.3   Nigeria
       12.7.4   South Africa
       12.7.5   Others
13   Regulatory Framework
   13.1   Regulatory Overview
   13.2   US FDA
   13.3   EU EMA
   13.4   INDIA CDSCO
   13.5   JAPAN PMDA
   13.6   Others
14   Clinical Trial Analysis
   14.1   Analysis by Trial Registration Year
   14.2   Analysis by Trial Status
   14.3   Analysis by Trial Phase
   14.4   Analysis by Therapeutic Area
   14.5   Analysis by Geography
15   Grant Analysis
   15.1   Analysis by Year
   15.2   Analysis by Amount Awarded
   15.3   Analysis by Issuing Authority
   15.4   Analysis by Grant Product
   15.5   Analysis by Funding Institute
   15.6   Analysis by Departments
   15.7   Analysis by Recipient Organization
16   Funding and Investment Analysis
   16.1   Analysis by Funding Instances
   16.2   Analysis by Type of Funding
   16.3   Analysis by Funding Amount
   16.4   Analysis by Leading Players
   16.5   Analysis by Leading Investors
   16.6   Analysis by Geography
17   Strategic Initiatives
   17.1   Analysis by Partnership Instances
   17.2   Analysis by Type of Partnership
   17.3   Analysis by Leading Players
   17.4   Analysis by Geography
18   Supplier Landscape
   18.1   Market Share Analysis, By Region (Top 5 Companies)
       18.1.1   Market Share Analysis: Global
       18.1.2   Market Share Analysis: North America
       18.1.3   Market Share Analysis: Europe
       18.1.4   Market Share Analysis: Asia Pacific
       18.1.5   Market Share Analysis: Others
   18.2   Amgen Inc.
       18.2.1   Financial Analysis
       18.2.2   Product Portfolio
       18.2.3   Demographic Reach and Achievements
       18.2.4   Company News and Developments
       18.2.5   Certifications
   18.3   Novartis AG
       18.3.1   Financial Analysis
       18.3.2   Product Portfolio
       18.3.3   Demographic Reach and Achievements
       18.3.4   Company News and Developments
       18.3.5   Certifications
   18.4   Pfizer Inc.
       18.4.1   Financial Analysis
       18.4.2   Product Portfolio
       18.4.3   Demographic Reach and Achievements
       18.4.4   Company News and Developments
       18.4.5   Certifications
   18.5   Bluebird Bio, Inc.
       18.5.1   Financial Analysis
       18.5.2   Product Portfolio
       18.5.3   Demographic Reach and Achievements
       18.5.4   Company News and Developments
       18.5.5   Certifications
   18.6   Castle Creek Pharmaceutical Holdings
       18.6.1   Financial Analysis
       18.6.2   Product Portfolio
       18.6.3   Demographic Reach and Achievements
       18.6.4   Company News and Developments
       18.6.5   Certifications
   18.7   Bristol-Myers Squibb
       18.7.1   Financial Analysis
       18.7.2   Product Portfolio
       18.7.3   Demographic Reach and Achievements
       18.7.4   Company News and Developments
       18.7.5   Certifications
   18.8   Kite Pharma, Inc.
       18.8.1   Financial Analysis
       18.8.2   Product Portfolio
       18.8.3   Demographic Reach and Achievements
       18.8.4   Company News and Developments
       18.8.5   Certifications
   18.9   Vericel Corporation Inc.
       18.9.1   Financial Analysis
       18.9.2   Product Portfolio
       18.9.3   Demographic Reach and Achievements
       18.9.4   Company News and Developments
       18.9.5   Certifications
   18.10   Kolon TissueGene Inc.
       18.10.1   Financial Analysis
       18.10.2   Product Portfolio
       18.10.3   Demographic Reach and Achievements
       18.10.4   Company News and Developments
       18.10.5   Certifications
   18.11   Vertex Pharmaceuticals, Inc.
       18.11.1   Financial Analysis
       18.11.2   Product Portfolio
       18.11.3   Demographic Reach and Achievements
       18.11.4   Company News and Developments
       18.11.5   Certifications
   18.12   Spark Therapeutics, Inc.
       18.12.1   Financial Analysis
       18.12.2   Product Portfolio
       18.12.3   Demographic Reach and Achievements
       18.12.4   Company News and Developments
       18.12.5   Certifications
   18.13   CORESTEM Inc.
       18.13.1   Financial Analysis
       18.13.2   Product Portfolio
       18.13.3   Demographic Reach and Achievements
       18.13.4   Company News and Developments
       18.13.5   Certifications
   18.14   Biogen Inc.
       18.14.1   Financial Analysis
       18.14.2   Product Portfolio
       18.14.3   Demographic Reach and Achievements
       18.14.4   Company News and Developments
       18.14.5   Certifications
   18.15   Dendreon Pharmaceuticals LLC.
       18.15.1   Financial Analysis
       18.15.2   Product Portfolio
       18.15.3   Demographic Reach and Achievements
       18.15.4   Company News and Developments
       18.15.5   Certifications
   18.16   JCR Pharmaceuticals Co. Ltd.
       18.16.1   Financial Analysis
       18.16.2   Product Portfolio
       18.16.3   Demographic Reach and Achievements
       18.16.4   Company News and Developments
       18.16.5   Certifications
19   Global Cell and Gene Therapy Market – Distribution Model (Additional Insight)
   19.1   Overview
   19.2   Potential Distributors
   19.3   Key Parameters for Distribution Partner Assessment
20   Key Opinion Leaders (KOL) Insights (Additional Insight)
21   Payment Methods (Additional Insight)
   21.1   Government Funded
   21.2   Private Insurance
   21.3   Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Request Sample

Purchase Full Report

Datasheet

$ ~~2969~~ $2699

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~5499~~ $4999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~6599~~ $5999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~7699~~ $6999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER